All posts by medical

Greys Anatomy season 16 episode 12 preview: Who ordered the awkward family dinner? – Culturess

Even thoughGreys Anatomy is truly at its best when its focusing more on dramatic medical cases than on the often drawn-out drama of its doctors personal lives, it doesnt hurt to mix things up every now and then and focus on a more everyday event. Like a family dinner, for instance.

It seems Catherine and Richard have decided to invite the family to a meal. Which technically includes Maggie, since shes Richards biological daughter. Jackson is also bringing his girlfriend, who he started dating arguably a little too soon after breaking up with Maggie (and after his girlfriends fiance died unexpectedly its a long story).

For once, the episode promo for this week didnt give away too much about the upcoming plot. We know Maggie has returned to Grey Sloan, though we arent sure why or whether or not its temporary. We also know that this will be another crossover withStation 19, or will at least prominently feature a few characters from the spin-off series.

What can we expect? Plenty of passive aggressive commentary between Maggie and Jackson. Hilarious commentary from Dean (hes comic relief in the absolute best way possible). Oh, and lets not forget the meltdown thats about to commence between Richard and Catherine.

Watch the promo trailer for The Last Supper here:

These two have been quietly feuding for a while now, and this episode might actually be the one that breaks them apart for good.

Its a shame that Catherines cancer storyline didnt bring them closer together as it could have. Its even more disappointing that it didnt change her as a character at all. Shes just as awful as she was before, at least in most situations weve seen her in lately (not that there have been many).

Richard really hasnt done anything wrong. He tried his best to support his wife when she needed him most. And sure, there were some phone calls he should have answered and didnt. But at what point do you stop trying to connect with someone who doesnt seem to want it?

IfGilmore Girls taught us anything, its that family dinners can be some of the most disastrous events in our favorite characters lives. They can sometimes, however, lead to some of the best and most memorable moments of all.

There will be fighting theres no denying that. But maybe, just maybe, one or two people at that table at a minimum will walk away better off than they were when they sat down.

There are actually a lot of fans rooting for Maggie and Dean (fromStation 19) to get together. And honestly? It just might work.

Follow this link:
Greys Anatomy season 16 episode 12 preview: Who ordered the awkward family dinner? - Culturess

Do Maggie and Jackson End up Together on ‘Grey’s Anatomy’? They Might – Distractify

Do Maggie and Jackson End up Together on 'Greys Anatomy'? They MightAcceptWe allow third parties to collect information which we use for business purposes, for more info read CCPA section in the privacy policy page.AcceptBrowsers may block some cookies by default. Click accept to allow advertising partners to use cookies and serve more relevant ads. Visit our privacy policy page for more information.Source: ABCBy Chrissy Bobic

41 minutes ago

The medical drama Greys Anatomy is no stranger to the world of will they/wont they when it comes to couples. If someone isn't in an active love triangle, then they are probably going back and forth between loving and hating another character.

So, even if Jackson and Maggie aren't together now, there is always the chance that they could find themselves in love all over again. This is Greys Anatomy, after all. Nothing is ever truly off the table.

The Feb. 6 episode brings Jackson and Maggie together again in an awkward family dinner to end all dinners. Their parents are married but might be divorcing, and Jacksons new girlfriend, Vic, from Station 19 is in attendance.

She is also bringing along a friend from the station who at one time flirted with Maggie. But instead of solidifying Maggie and Jacksons own separation, the dinner could, in fact, bring them back together.

The biggest argument against Maggie and Jackson being together when they first became a thing was the fact that they are sort of related. Maggies birth father, Richard, who she didn't know until a few years ago, is married to Jacksons mom, Catherine.

Right now, however, it looks like Richard and Catherine are close to divorce. If that happens, then fans might be more inclined to ship Jackson and Maggie together and the Greys Anatomy powers that be could make it happen.

Maggie is going through something major right now. Not only did she lose a patient on the table, but that patient was her cousin and the family is now taking legal action against Maggie. As one Greys Anatomy fan pointed out on Twitter, Maggie needs the people around her to help her get through this, including Jackson.

Maggies crisis could be the thing that brings her and Jackson back together for good.

On the other hand, the timing might be all wrong for Maggie. "ug not Maggie & Jackson probably getting back together. Also, Maggie isn't in the right headspace so don't try to be romantic Jackson," one fan tweeted.

Maybe after she works through her personal issues, she can mend things with Jackson. But the timing probably isn't great for now.

Plus, Maggie and Jackson's relationship has been sort of hard to define from the start at least for die-hards on reddit. For that reason, it's hard to imagine Jackson and Maggie getting back together permanently in a romantic sense.

Maybe they can be friends again, but the romantic aspect of their relationship could be gone for good.

Instead of Jackson, Maggie could end up getting together with Dean from Station 19. In a Season 15 crossover episode, Dean actually asked Maggie out on a date. Nothing came from it, of course, but now that she and Dean are going to be thrown together at a family dinner on Greys Anatomy, she could take him up on that date.

Although there are theories about Maggie and Jackson ending up together on Greys Anatomy, its clear that fans have mixed emotions about the two of them being endgame or even together at all. At the very least, lets hope they can be friends again.

Watch Greys Anatomy on Thursdays at 9 p.m. ET on ABC.

Go here to see the original:
Do Maggie and Jackson End up Together on 'Grey's Anatomy'? They Might - Distractify

The Neuroscience Behind What the Crowd Thinks – INSEAD Knowledge

Information about how others feel about pain has an outsized effect on our own response to it.

Pain is central to the human experience. While some suffer in silence, others are wildly vocal about the slightest prick of pain. Understanding pain is necessary to treat and manage it across many acute and chronic medical conditions. At this point in time, science has unveiled some basic physiological mechanisms and the most important networks in the brain where pain is processed. We have developed a better understanding of how pain signals are transmitted from the skin to the brain.

Surprisingly, neuroscience shows us that our experience of pain is not entirely our own the opinions of others can play an outsized role. In other words, peer opinions affect not only our behaviour, but our experience and bodily responses as well. As I explain below, this finding has broad implications for business.

Responses to learned experience and social information

In a recent experiment with Marieke Jepma (University of Amsterdam), Marina Lopez-Sola (Cincinnati Childrens Hospital) and Tor Wager (University of Colorado Boulder), we found that social information about pain increases activity in a particular part of the brain, different from those activated by expectations that we develop based on learning from our own experience.

The aim of this study was to disentangle the components of how we form expectations about pain and how these expectations can influence what we experience. On the one hand, our expectations can be based on our own experiences, for instance, if we recently had a painful medical procedure. On the other hand, expectations are often formed based on what other people tell us about their experiences; social information about how more or less painful events can be. We found that different networks in the brain are involved depending on the source of information.

Each participant in our experiment received 96 short bursts of heat on their leg while in an MRI scanner. The heat was about as hot as a hot coffee cup; painful but bearable for most people. The 36 participants were shown images that indicated either warmer or cooler temperatures (learned experience) and shown an image of a range of opinions about the pain (social information). During the MRI, they rated the one-second touch of heat and we could measure their brains responses.

For learned experiences, participants saw one image that was typically followed by less pain (an animal) and one image that signalled more heat (a vehicle). This allowed us to establish the connection between learned experience and the participants ratings of pain.

Our hypothesis was that the high-pain learning cue, compared to the low-pain cue, would increase the effect of pain, even when followed by a medium temperature. We found this to be true; however, we also found that not all participants learned from the experience.

On the other hand, we found that social information the image showing how others responded to the heat had a significant effect on participants pain responses. This social information effect remained strong, even after 96 trials. Moreover, not only their self-reported experiences, but also their bodily responses, changed to conform with social information. For instance, their palms were sweatier following pain when they were shown the high-pain ratings of others compared to low-pain ratings of others.

Using fMRI, we were also able to see different brain activity patterns in response to the two types of effects. Social information effects were found in the anterior insula, frontal and parietal areas of the brain; specifically its effects on pain were related to activity in the frontoparietal and dorsal attention networks. The learned or conditioned effects were found in limbic areas and in the cerebellum.

Feedback effects

Now that we see how the brain reacts to social information in terms of pain, we can re-examine how the opinions of others impact our own reactions and subsequent choices. Social information is no longer just what our friends and family think. With the proliferation of social media and consumer ratings on internet platforms such as Facebook, Amazon, Yelp and others, social influence happens on a much larger scale. With fake reviews and the possibility of bought ratings on Amazon and other platforms, how do we filter social information?

Given that our research shows that social ratings influence experience, we should also start considering feedback effects. In a recent study with Jepma, we have demonstrated that strong beliefs about pain can prevent learning and lead to a confirmation bias.

As a potential implication for business, if many genuine people have rated a product or a service positively, others experience may be influenced by these ratings. The opposite could be observed for negative ratings. Since ratings influence how the product is perceived, these in turn impact new consumer ratings. One feeding off the other, these effects could create feedback loops, which lead to overly positive or overly negative product ratings.

Self-regulation and the group

Based on the strength of the effects of social information, we need to carefully consider and measure the real-world impact of social ratings and how to potentially regulate them. When ratings are authentic, they can be helpful. Yet, they need to be taken with a grain of salt and a closer look at their authenticity. People need to be better informed about social influence effects, the impact of ratings, and where ratings could come from. Yet, this might be challenging, since most people are unaware of how much they are influenced by others.

In our study, we didnt tell the participants who the other people rating pain were, so the social information was not related to a specific group. Other studies have investigated the role of in-group versus out-group information. In general, people are much more influenced by in-group ratings originating from people who are like them or who are attractive and much less by out-groups. One study with children found that they were more willing to wait for a marshmallow if the rest of their in-group (kids in the same group) also waited. They were less likely to conform if an out-group of other children waited for their treat. Thus, social influence also depends on the source of the information, which may align us even closer to people we already identify with. Together with so-called filter bubbles, this may lead to increased polarisation of in-groups and greater dissent with other groups.

Your own opinion

The large effects of social information have implications for decision making in real life. In our data-driven world, our opinions and behaviours are constantly quantified. Maybe its time to step back from constant evaluation on social media and from checking restaurant ratings before trying one. Our research shows that social information changes not only our overt behaviour, but also strongly colours our judgement. Maybe its time to re-focus our attention to our own actual sensations and prioritise mindful experiences in order to shake the confirmation bias that occurs when we are dazzled by the number of stars next to a product or restaurant.

Leonie Koban is a post-doctoral research fellow in Marketing at INSEAD.

Dont miss our latest content. Download the freeINSEAD Knowledge apptoday.

Follow INSEAD Knowledge onTwitterandFacebook.

Read the rest here:
The Neuroscience Behind What the Crowd Thinks - INSEAD Knowledge

The Neuroscience of Picking a Presidential Candidate – The New Yorker

In the lab, a broad picture window thats actually a one-way mirror looks into the testing room, where subjects are wired up to sensors as they watch videos. The perimeter of the testing room itself is lined with small carrels, each with its own computer workstation. A Webcam is perched atop each monitor. I had already gone through a demonstration of SPARK Neuros system myself, watching a couple of old Super Bowl ads and a grainy clip of the movie Crash, and had seen, precisely, the peaks and valleys of my attention. According to what Ive seen so far, Gerrol said, it seems like you feel empathy and emotion in strong ways, but you do not seem like someone who has massive highs and lows. It was an anodyne analysis that didnt tell me anything I didnt know, but it wasnt supposed to. The more interesting test would happen when the dozen volunteers began to react to the candidates onstage in Des Moines.

To read emotions and gauge attention, a tight plastic cap outfitted with an array of highly conductive metal electrodes was placed over the participants heads as they concentratedor noton a relaxing, intentionally monotonous beach scene playing on the screen in front of them. They could watch waves forming in the middle distance and hear surf lap the shore. Once the electrodes were in place, the electroencephalogram (EEG) cap began to broadcast electrical signalsbrain wavesevery four milliseconds, establishing each participants baseline: essentially, the brain at rest. This would give the researchers a way to measure the intensity of a participants reactions once that tranquil scene was replaced by the rough-and-tumble of the debate. Our brains share a lot in common with how we process information, but were not all coming into it at the same starting point, Gerrol explained. Maybe youre having a good day. Maybe youre having a bad day. Maybe you just had way too much coffee. And so its really important to understand each persons starting point, so the change in the difference from that baseline becomes much more meaningful than some absolute scale.

The researchers also clipped a heart-rate monitor to each persons left earlobe to keep track of vascular changes and attached a galvanic-skin-response (GSR) sensor to their middle and index fingers to measure sweat production, the way a lie detector does. (Sweaty hands typically occur when someone is anxious. Sweat conducts electricity; the greater the signal coming from the GSR, the greater the arousal.) As the participants looked at the computer monitor, the researchers used an eye tracker to see, instantly, exactly where on the screen they were looking, while a Webcam observed tiny, nearly imperceptible changes in their facial expressions. According to Gerrol, EEG makes up the majority of the signal, GSR contributes to converging evidence around emotional arousal, and facial expressions occasionally help.

How SPARK Neuros proprietary algorithm weights all of this data, Gerrol said, is the secret sauce. Its the way that we combine different sensors, from brain activity to peripheral-nervous-system activity, which can provide insights about the nature of emotions, he told me. Sometimes that is clear joy or clear fear or clear anger. However, keep in mind we are measuring emotions, not like versus dislike. Sometimes a politicianwill purposefully evoke fear as part of their strategy, perhaps scaring people, for example, about war and its consequences or about terrorism. Or they will use anger as a strategic rhetorical device, perhaps evoking anger at a lack of action on climate change. In other words, even if we read anger, that does not mean that the person is angry at the candidate; it very well may mean that the candidate did a good job of riling them up on a topic they care about.

Around midnight, when the debate was over, a couple of the volunteers stayed behind to talk with Gerrol and me. We had already seen a graph of the participants reactions; they had not. Michael Bradley Cohen, a thirty-three-year-old actor and licensed New York City tour guide, who is white, had snapped to attention when Bernie Sanders spoke and flatlined when it was Bidens turn. I came here trying to hold my top three candidatesButtigieg, Sanders, and Warren, in that orderin the same place in my head, Cohen told us. But the data appeared to show something else. His strongest reactions were to Warren, Sanders, and then Buttigieg. When Warren, in an advertisement, spoke about a wealth tax, she really got Cohens attention, even though he thought he had been more attuned to a Buttigieg ad that, comparatively, had not elicited much of an emotional response. During the debate, Cohens reaction to Warrens answer to a question about her fitness to serve as Commander-in-Chief showed a sustained set of spikes, each one climbing higher as she continued to talk, like notes moving up a musical staff. When Gerrol pointed this out, Cohen was, as Gerrol predicted, suddenly introspective. I think it was actually really poignant to me, hearing a womans voice on the stage. I know she spoke after Senator Klobuchar, but to hear her speak about this in a way that I trusted felt really good at the time. Yeah, it showed up. Thats what it was. And probably what were also witnessing is that I had a bit of a glow, like, Oh, theres the girl in class that I like, and that might also be what was picked up on.

Faradia Kernizan, who is twenty-nine and black, recently finished a masters degree in public health. She arrived that evening already a Warren supporter, and it showed in the data. When Warren spoke, Kernizans attention moved from her baseline of two all the way up to eight and a half, a jump that Gerrol found especially telling. I mean, thats what I might expect to see if you were watching a horror movie, he said, not something like a debate, with its dry content. But Kernizan didnt find it dry at all. This is our future, she said. I mean, this is all so exciting. Were at a point where, I mean, hopefully, things will change and maybe we get a different leader, and I think were at a point where we can get somebody that we really believe in.

She was paying special attention to Warrens views on foreign policy, she said, so she would be able to repeat them to friends and family members she hoped to convince to vote for Warren. But Kernizan was also attuned to some of the other candidates as well, like Biden, since there was a chance that he would be the nominee, and Sanders, whom she supported in 2016. That Cohen and Kernizan were not especially moved by the political ads didnt surprise Gerrol. My impression, having studied thousands and thousands of ads, is that political ads are especially boring. The Bloomberg ad, Cohen said, looked like he was running for President in 1988. As Cohen watched it, his attention dropped to his baseline.

A few days after we had gone through this exercise, I got an e-mail from Gerrol telling me about a third participant, whose attention graph looked similar to Cohens and Kernizans, with significant surges of attention when Sanders and Warren were speaking. The difference was that, unlike Cohen and Kernizan, that participants attention was an expression of his antipathy: Sanders and Warren were his least favorite candidates. It was a perfect illustration of the danger of conflating attention with affection. We had seen something similar, too, when Cohens graph showed his attention picking up every time one of the candidates mentioned Trump. Yeah, when we hear the name Voldemort, Cohen said, we all have a response.

Go here to see the original:
The Neuroscience of Picking a Presidential Candidate - The New Yorker

Q&A: Student conducts research on stress in adolescents – The Ithacan

For many students in the Ithaca College School of Health Sciences and Human Performance, conducting their own research is the ultimate goal. Senior Justina Snyder is already well on her way to achieving it.

Snyder is a clinical health studies major, which is part of the sixyear physical therapy program, and she has minors in neuroscience, psychology and honors. Snyder was inspired to start her own research project in the fall of her sophomore year after taking a behavioral neuroscience course taught by Tamara Fitzwater, assistant professor in the Department of Psychology.

With Fitzwaters guidance, the two worked together to study how physical stress impacts the brains and behaviors of adolescents. Last spring, Snyder and Fitzwater applied for the Academic Challenge Grant from the Office of the Provost, which provides funding to student-faculty teams involved in collaborative research projects. Synder said she plans to use her findings in her honors thesis, a final project that is required for seniors completing the honors minor in interdisciplinary studies.

Staff writer Ryan Bieber sat down with Snyder to discuss the inspiration for her research and the process of writing her thesis.

This interview has been edited for length and clarity.

Ryan Bieber: What made you want to major in physical therapy?

Justina Snyder: I always kind of knew I wanted to be in the medical or health care field, and, when I was looking at different options, I realized PTs actually get to sit down with their patients and develop a rapport. I really like building connections with people, and I thought that was a better way for me to be able to help people meet their goals and get better.

RB: How did you come up with the idea for your honors thesis?

JS: I knew stress was always a really big topic of discussion, and I kind of wanted to tie it into PT. I was kind of thinking about how stress impacts peoples ability to perform tasks and tying that into PT and neuroscience in general to see how stress affects the brain.

RB: How has the honors program played a role in your research?

JS: The whole purpose of the Honors Program is interdisciplinary, so they want you to take classes outside of your given major and explore different themes and topics. I really like this project because its taking my psych and neuroscience background and pairing it with PT and the classes Ive taken within the Honors Program and kind of putting it all together. Its cool to see things from different perspectives both in the neuroscience and psychology realms.

RB: What was your reaction when you found out you received the grant?

JS: We were really happy that we were able to secure the money to do the project. It was kind of nerve-racking because if we didnt get this money, I dont know that our project would have been able to happen. Science research in general is just really expensive, so we knew this was a great way we could get funding for the project.

RB: What phase are you at in your research?

JS: We did all the hands-on work last semester. This semester is really geared toward me writing my thesis. Were exploring the opportunity to present at the Whalen Symposium here on campus, which is kind of a bucket list thing for me.

RB: Whats the most important takeaway from your research?

JS: Research projects are a fluid process, so you have to adjust. Theres going to be challenges and deadlines or something might not go as planned, and you just have to make adjustments to it. Its been a great learning process.

RB: How do you balance all the classes in your major and minors with your research?

JS: It just comes down to organization and having a passion for things. Its about all of the knowledge Ive gained, the experiences Ive had and the people Ive met. Its about having the drive and the passion to do it.

Read more:
Q&A: Student conducts research on stress in adolescents - The Ithacan

Study Links Autism To ‘Insulation’ That Coats Brain Cells And Speeds Signals : Shots – Health News – NPR

This image from an electron microscope shows a cross-sectional view of an oligodendrocyte (blue) among nerve fibers coated with myelin (dark red). In models of autism spectrum disorder, oligodendrocytes appear to create too much or too little myelin. Jose Luis Calvo/Science Source hide caption

This image from an electron microscope shows a cross-sectional view of an oligodendrocyte (blue) among nerve fibers coated with myelin (dark red). In models of autism spectrum disorder, oligodendrocytes appear to create too much or too little myelin.

Scientists have found a clue to how autism spectrum disorder disrupts the brain's information highways.

The problem involves cells that help keep the traffic of signals moving smoothly through brain circuits, a team reported Monday in the journal Nature Neuroscience.

The team found that in both mouse and human brains affected by autism, there's an abnormality in cells that produce a substance called myelin.

That's a problem because myelin provides the "insulation" for brain circuits, allowing them to quickly and reliably carry electrical signals from one area to another. And having either too little or too much of this myelin coating can result in a wide range of neurological problems.

For example, multiple sclerosis occurs when the myelin around nerve fibers is damaged. The results, which vary from person to person, can affect not only the signals that control muscles, but also the ones involved in learning and thinking.

The finding could help explain why autism spectrum disorders include such a wide range of social and behavioral features, says Brady Maher, a lead investigator at the Lieber Institute for Brain Development and an associate professor in the psychiatry department at Johns Hopkins School of Medicine.

"Myelination could be a problem that ties all of these autism spectrum disorders together," Maher says. And if that's true, he says, it might be possible to prevent or even reverse the symptoms using drugs that affect myelination.

"If we get to these kids really early, we might be able to change their developmental trajectory and improve their outcomes," Maher says.

"It's possible to make these cells healthier," adds Dr. Daniel Weinberger, director of the Lieber Institute and a professor at Johns Hopkins. "And it's never been a target of treatment in autism."

The study adds to the evidence that myelination problems are present in "several developmental disorders and in particular in autism," says Dr. Flora Vaccarino, a professor in the neuroscience department at Yale who was not involved in the research.

It also shows how one faulty regulatory system in the brain can lead to either too much myelination or too little, she says. And that may help explain why people with autism spectrum disorders may have brains that are either unusually large or unusually small.

Researchers involved in the study came upon the myelination problem while looking for something else.

They were studying brain cells in mice with a gene mutation that causes Pitt-Hopkins syndrome, which can include features of autism spectrum disorder. "We saw a signature that suggested there might be something wrong with myelination," Maher says. "So that was pretty surprising to us."

More experiments confirmed that "there was a clear deficit," in the cells that control myelination, which are called oligodendrocytes, he says. This was true not only in mice with the Pitt-Hopkins syndrome, but in other mouse models of autism, too.

Next, a biostatistics expert named Andrew Jaffe looked at a genetic analysis of brain tissue from people with autism who had died. And that experiment also found problems with the system that controls myelination.

To fully understand what's going on though, the problem needs to be studied in developing brain tissue, Vaccarino says.

That should be possible, she says, using tiny clusters of human brain cells called brain organoids, which can be grown in a petri dish. Vaccarino's lab has created brain organoids from the cells of people with autism spectrum disorder, which might reveal how the myelination problems begin, she says.

Brain myelination "really does not start in earnest until the first year or two of life," Weinberger says. "And this is around the time that autism is first apparent."

That might eventually mean a treatment that corrected a problem with myelination could help children who are diagnosed early in life, he says. Several such treatments are being developed to treat people with multiple sclerosis, a disease that erodes myelin.

Go here to see the original:
Study Links Autism To 'Insulation' That Coats Brain Cells And Speeds Signals : Shots - Health News - NPR

Neuroscience Antibodies & Assays Market 2020 Future Growth by In Depth Industry Analysis, Size, Trends and Forecast by 2026 – Jewish Life News

New Jersey, United StatesThe report titled, Neuroscience Antibodies & Assays Market Size, Status and Forecast 2020-2026 is comprehensively analyzed by the authors of the report to help players and investors to gain deep understanding of important drivers and restraints, segments, regions, and the vendor landscape. The research analysts have shed light on each and every aspect of the Neuroscience Antibodies & Assays industry and how it may be influenced in the coming years. The revenue, production, consumption, CAGR, share, and other forecasts for the Neuroscience Antibodies & Assays industry are accurate and highly reliable. They have been verified with the help of advanced tools and industry experts. Overall, the report comes out as a useful guide for both leading players and new entrants to obtain growth in the Neuroscience Antibodies & Assays industry.

Neuroscience Antibodies & Assays Market was valued at USD 2.42 Billion in 2018 and is projected to reach USD 5.14 Billion by 2026, growing at a CAGR of 9.7% from 2019 to 2026.

Get PDF template of this report: @ https://www.verifiedmarketresearch.com/download-sample/?rid=28342&utm_source=JLN&utm_medium=009

Key companies functioning in the global Neuroscience Antibodies & Assays Market cited in the report:

Almost all major players operating in the Neuroscience Antibodies & Assays market are included in the report. They have been profiled based on recent developments, geographic expansion, market presence, gross margin, net profit, applications, product portfolio, and a number of other factors. The research analysts have made a brilliant attempt to explain key changes in the vendor landscape, the nature of competition, and future plans of leading players in the Neuroscience Antibodies & Assays industry.

Neuroscience Antibodies & Assays Market: Segment Analysis

To broaden the understanding of the reader, the report has also studied the segments including product type, application, and end user of the Neuroscience Antibodies & Assays market in a comprehensive manner. Apart from that, the market.

Readers of the report can receive in-depth information about different product type and application segments of the Neuroscience Antibodies & Assays industry. The segments included in the report are studied in great detail by the experienced research analysts. They have been analyzed on the basis of several parameters, including share, growth rate, and future growth potential in the Neuroscience Antibodies & Assays industry.

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=28342&utm_source=JLN&utm_medium=009

Neuroscience Antibodies & Assays Market: Regional Analysis :

As part of regional analysis, important regions such as North America, Europe, the MEA, Latin America, and Asia Pacific have been studied. The regional Neuroscience Antibodies & Assays markets are analyzed based on share, growth rate, size, production, consumption, revenue, sales, and other crucial factors. The report also provides country-level analysis of the Neuroscience Antibodies & Assays industry.

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Neuroscience Antibodies & Assays industry.

Market Segmentation: This section provides detailed analysis of type and application segments of the Neuroscience Antibodies & Assays industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Neuroscience Antibodies & Assays industry.

Market Dynamics: The report offers deep insights into the dynamics of the Neuroscience Antibodies & Assays industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Neuroscience Antibodies & Assays industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Neuroscience Antibodies & Assays industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Neuroscience Antibodies & Assays industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Neuroscience Antibodies & Assays industry.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Neuroscience-Antibodies-&-Assays-Market/?utm_source=JLN&utm_medium=009

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Our research studies help our clients to make superior data-driven decisions, capitalize on future opportunities, optimize efficiency and keeping them competitive by working as their partner to deliver the right information without compromise.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email:[emailprotected]

Read the original post:
Neuroscience Antibodies & Assays Market 2020 Future Growth by In Depth Industry Analysis, Size, Trends and Forecast by 2026 - Jewish Life News

Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12 – Yahoo Finance

DUBLIN, Ireland, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

The conference call will be made available on the Company's website at http://www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.

To access the call via dial-in, please dial(877) 887-5215 (U.S. and Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 1758808. A replay of the call will be available until February 26, 2020 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 1758808.

About Prothena Prothena Corporation plc is a clinical-stage neuroscience company with expertise in protein misfolding, focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothenas partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinsons disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimers disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Our proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target A (Amyloid beta) for the potential treatment of Alzheimers disease.

Media & Investor Contact:

Ellen Rose, Head of Communications650-922-2405, ellen.rose@prothena.com

See the article here:
Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12 - Yahoo Finance

Neuroscience Market Application 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2026 -…

Neuroscience Market Overview

The Neuroscience Market report released and promoted by CMI draw out historical, existing, and forecast valuation of the Neuroscience industry till 2026. The report highlights the market essentials, opportunities, regional market, Emerging Growth Factors, market challenges, forecast and competitors joined with their market share. The fundamental purpose of Neuroscience Market report is to provide a appropriate and strategic analysis of the Neuroscience industry.

Get FREE Sample Copy with Graphs and Charts @ https://www.coherentmarketinsights.com/insight/request-sample/2487

The Market structure covers the value chain, player categories, product ranges, key players presence across products and end user segments of the market. The report also provides a snapshot of key competition, market trends with forecast over the next 5 years, anticipated growth rates and the principal factors driving and impacting growth market data and analytics are derived from a combination of primary and secondary sources.

The research process involved the study of various factors affecting the industry, including the government policy, market situation, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges.

Top merchant analysis is one of the key component and is exceptionally helpful for each player to comprehend focused scene in the market. Major key companies present in Neuroscience market report are:Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Blackrock Microsystems LLC, Femtonics Ltd., Intan Technologies, LaVision Biotec GmbH, Mediso Medical Imaging Systems, Neuralynx Inc., NeuroNexus Technologies, Inc., Newport Corporation, Plexon Inc., Noldus Information Technology, Scientifica Ltd., Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.

Neuroscience Market report is the believable source for gaining the market research that will exponentially accelerate your business. Additionally, it Presents new task SWOT examination, speculation attainability investigation, and venture return investigation.

Market Event Factors Analysis

Market driver

Increasing market invasion of new technolgies.

For a full detailed, view our report

Market challenge

Stringent regulatory challenges in Neuroscience applications.

For a full detailed, view our report

Market trend

Rising demand for Neuroscience in market.

For a full detailed, view our report

Request Exclusive Sample PDF Of This Report): https://www.coherentmarketinsights.com/insight/request-pdf/2487

Key questions answered in Neuroscience Market 2020 2026 report:

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is key factor driving this market?

What are the challenges to market growth?

Who are the major key vendors in this market space?

What are the market opportunities, market risk and market overview and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

In the end Neuroscience Market Report delivers conclusion which includes Research Findings, Market Size Estimation, Market Share, Consumer Needs/Customer Preference Change, Data Source. These factors will increase business overall.

Buy This Research Study Report @ https://www.coherentmarketinsights.com/insight/buy-now/2487

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Visit The Blog:http://bit.ly/Rajkumar123

Read the original here:
Neuroscience Market Application 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2026 -...

BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal SymptomsCompany is preparing to…

NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that its Investigational New Drug (IND) application for BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of opioid withdrawal symptoms.

The FDA clearance of our IND application for opioid withdrawal, a fourth indication, is an important step in our plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501, commented Vimal Mehta, Chief Executive Officer of BTI. Opioid overdose is reported as the number one cause of death for those under 50 years old in the U.S., and the distressing and challenging symptoms that come with opioid withdrawal are a primary reason for relapse. There is an urgent need for better treatment options to help manage the debilitating withdrawal symptoms and aid this underserved population from continued opioid abuse. BXCL501, our investigational non-opioid therapy, may offer key advantages to treating symptoms due to its intrinsic potency and favorable delivery method. We believe this study will build on the encouraging results we observed in our intravenous (IV) Dex trial, which appeared effective in reducing opioid withdrawal symptoms.

Opioid withdrawal is an emotional and physiological medical condition that may be driven by the excessive drive of noradrenergic neurons that originate from the locus coeruleus in the brainstem. BXCL501 selectively activates alpha-2a adrenergic receptors, which decreases excessive neuronal firing, alleviating the physiological symptoms of opioid withdrawal.

The RELEASE trial is a multicenter, randomized, double-blind, placebo-controlled, ascending-dose Phase 1b/2 study designed to evaluate the safety, pharmacokinetics, tolerability and efficacy of BXCL501 in patients experiencing symptoms of opioid withdrawal. This study will enroll subjects with opioid use disorder who are physically dependent on opioids. Patients will be randomized into multiple dose cohorts of BXCL501, or matching placebo, administered twice daily for five days. The study will assess opioid withdrawal symptoms using both the Clinical Opiate Withdrawal Scale and Short Opiate Withdrawal Scale of Gossop over a 10-day period.

About BXCL501BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in a Phase 1b/2 trial for the treatment of agitation associated with dementia, and the Company is preparing to initiate the Phase 1b/2 RELEASE trial of BXCL501 for the treatment of opioid withdrawal symptoms.

About Opioid Drug Withdrawal:

According to the Centers for Disease Control and Prevention (CDC), the misuse of and addiction to opioids is a serious national crisis and is the leading cause of death in the U.S. for those under 50 years old. Between 1999-2017, almost 400,000 people died from an overdose involving an opioid, with greater than 47,000 deaths occurring in 2017 alone. The CDC estimates the total "economic burden" of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment and criminal justice involvement. Opioid withdrawal is a condition characterized by symptoms such as anxiety, agitation, sleep problems, muscle aches, runny nose, sweating, nausea, vomiting, diarrhea and drug craving that occur after stopping or reducing the use of opioids in anyone with physical dependence on opioids.

About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com/.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the effects of BXCL501 treatment on opioid withdrawal symptoms and the timing of clinical development initiatives and trials for BXCL501. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and on the Companys website at http://www.bioxceltherapeutics.com.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Source: BioXcel Therapeutics, Inc.

View post:
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal SymptomsCompany is preparing to...